Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Actually, that's not true anymore. Under the Tax Cuts and Jobs Act (TCJA, 2018), any company can carry a net loss forward for 20 years regardless of SIC. In addition, the CARES act (2020) added the ability of a company to use a NOL as a 5 year carryback, which means that any company merging, can go back 5 years into their past taxes and immediately have any amount paid back to them by the IRS. Any company wanting to recover past tax burdens for immediate working capital could use any amount of this NOL, while carrying any remaining balance forward for up to 20 years. This is a golden opportunity for any company looking to go forward, and this talk of it having to be a mining company is only a myth and scare tactic.
Actually, that's not true anymore. Under the Tax Cuts and Jobs Act (TCJA, 2018), any company can carry a net loss forward for 20 years regardless of SIC. In addition, the CARES act (2020) added the ability of a company to use a NOL as a 5 year carryback, which means that any company merging, can go back 5 years into their past taxes and immediately have any amount paid back to them by the IRS. Any company wanting to recover past tax burdens for immediate working capital could use any amount of this NOL, while carrying any remaining balance forward for up to 20 years. This is a golden opportunity for any company looking to go forward, and this talk of it having to be a mining company is only a myth and scare tactic.
Correct, they were able to be restricted because they were shares given (not purchased) to existing shareholders many years ago.
The restricted shares came from a share bonus to shareholders many years ago. Those shares were never changed by the company to be not restricted. Since the shares were given, not purchased, ENTI was able to make them restricted. (Not sellable)
It means that some of your shares are restricted. Call them, and a supervisor can tell you the number that are. Just subtract that number from your total shares and you can sell the rest.
Not going to lie though Cash, after all the years we've had this one, I'm almost thinking just get what I can out of it so I can stop cussing every time I look at my positions list. LOL
I had the same issue. Called my broker and found out that out of the large number of shares I have, 26,014 of them were restricted. So, if you call and find out how many are restricted, you can sell the rest without any issues.
I personally think this is false drops to trigger stop losses so shorts can cover as much as possible. I'm looking at the sells/buys going by, and it's sells of less than 50 to drop, with thousands of buys coming in as stop losses are hit.
This is why stop loss orders are a bad idea with biotech stocks. Especially one where you know shorts are going to screw with you on a daily basis.
Got tied up on another call and just now able to join. You'll have to catch me up on the really good highlights. Glad I'm able to get on before questions though.
I will be.
That's correct, and it would make the .08 possible.
Doing some research on the PSC website, it appears as though not only have they filed for the phase 1 trial, but here's a quote from the page:
"The White House Coronavirus Task Force asked PSC to file for accelerated FDA approval for our first study, CoronaStem 1. We immediately submitted our FDA request and we now have FDA approval. As CoronaStem 1 gets launched, we will ask FDA for approval for treatment of a larger group of patients in need."
CoronaStem 1 is the precise product Sorrento just licensed.
https://personalizedstemcells.com/covid-19/
I think if we get even one unexpected good update on the pipelines tomorrow that we will see a significant increase in PPS. Being someone with COPD, I am particularly happy about today's product acquisition. Speaking purely out of selfishness, I can see that therapy helping my situation as well, and I would welcome the day I don't have to cough all of the time.
If memory serves, the announcement was that they were in 195 of the 240 stores.
LMAO, they aren't even close to Sorrento's pipeline. How about choosing a company that's even close to Sorrento's league for a comparison. I would love to see what TRVN news you thought could possibly compare to a game changing non-opiod pain med.
Absolutely possible to reach that level and more. Just the pain med line with be worth $10's of billions per year. At that point it's simply a product of revenues plus multiples to see how high the price could go.
LOL, I believe I already got myself on that list to go with last month. Looking forward to the trip!
Biotech is never a short term play unless you're day trading. If you truly do your DD on this company, you will realize that early summer '21 is when this stock will truly pay off. The real money for sorrento is in their cancer and pain lines. True, the covid portfolio could jumpstart their revenue generation, however, covid will fade in time, and the long term value is in the other portfolios.
Simply highlighting dates doesn't prove your point, or prove you aren't lying. Read the rest after your highlights. First note is already repaid, the other 3 are already partially repaid. Which means that your apocalyptic dilution statements are incorrect by your own "proof" offering. Sure you can say they are not lies, but deception by omission is still lying.
Well stated. Glad to see someone else that can do real DD, have real rational thoughts, and not all this made up crap I've been seeing on here. Cheers!
Agree. Looks like they are starting to run out of steam now. Should keep rising throughout the day now.
Shorts sure working overtime this morning. LOL Will be interesting to see how long they can hold it down.
Bid and ask both increasing now.
Well, I think it's fair to say that Dr. Ji is getting the hang of this bear trap thing. LOL
Sorrento Therapeutics, ViralClear Enter Into Agreement To Explore Combination Antibody Plus Antiviral Therapy Against Coronavirus
9:01 am ET September 30, 2020 (Benzinga)
Sorrento Therapeutics and ViralClear Enter Into Agreement to Explore Combination Antibody Plus Antiviral Therapy Against COVID-19
Sorrento to initiate testing with a selection of its agents in combination with ViralClear's anti-viral compound for possible synergistic anti-viral effect against SARS-CoV-2 in the preclinical model of Golden Syrian hamster.
ViralClear to contribute its oral antiviral Merimepodib (IMPDH inhibitor) which is currently in a Phase 2 trial in combination with remdesivir to treat COVID-19.
Sorrento to initially make available STI-1400 neutralizing antibody candidate for testing.
WESTPORT, Conn., Sept. 30, 2020 (GLOBE NEWSWIRE) -- ViralClear Pharmaceuticals, Inc. (Nasdaq BSGM) and Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", )))) announced the companies are exploring the synergistic potential of small molecules and antibodies combination therapies against COVID-19.
In general, multi-modal approaches are considered the most likely to succeed anti-viral strategies. Even with highly effective stand-alone therapies, a synergistic combination can be pursued to help reduce the effective dose needed of each individual agent and aim to ensure maximum effect.
The agreement between ViralClear Pharmaceuticals, Inc. ((Parent company BioSig Technologies, NASDAQ:BSGM) and Sorrento Therapeutics will allow for testing of merimepodib with neutralizing antibodies in the Golden Syrian hamster model of COVID-19.
The study will look for synergy at the effective doses between the two drugs already in human clinical trials and will try to specifically demonstrate that the combined benefits in strengthening and accelerating viral clearance exceed what each drug could deliver by itself.
Pending the outcome of these studies, the results might be presented to the FDA to support the initiation of a human clinical trial of the drug combination.
See, this is where we disagree. The company has stated that they are working to close out debt without further dilution. You keep making the erroneous statement that they will keep splitting and diluting. Your last response shows you aren't truly interested in debating possible outcomes for the company based on events and numbers, but simply your unfounded assumptions. Quick hint, when someone is level headed enough to have a reasonable debate, at least be decent enough to reciprocate.
Yes, but they do some modifications of the white label boxes, thus work to do, and inventory to build. Also have to take into account the investments in both materials and space for building/storing the shield products in addition to panel storage. Simply making the point that their expenses are not as simple as minor facility leases, etc, and all investments that needed to be made to move forward.
No, none of that is necessarily true. Yes, OTC stocks are for companies that are TRYING to make it to the big leagues because it is easier to do funding. (Toxic or not) However, it is not a foregone conclusion for any of your other follow up assumptions. GAXY seems to be taking the better road to include financing of operations outside of common stock usage (benefit of the acquisitions). While the expenditures grew, overall dilution did not. Therefore, the assumption has to be that they were able to get legitimate financing for operations. So, again, losses are common in growth, especially this kind of exponential growth in capacity. It is obvious to me from the 10-k that they are now able to get legitimate lower cost financing for much of what they are doing.
Cool promotion idea!
2019 inventory was completely different from today's inventory. 2019 inventory included things for movie theaters. This year it does not. Also, by making a major purchase of components, they would have significantly reduced the cost basis for those. Also, the operating expense increase is due to now having 4 primary locations. So, again, comparing last year's cost basis to this year's is completely misleading as they are two totally different animals. As GAXY gears up for panel production in addition to the company acquisitions, it is completely reasonable for the balance sheet to read as it does during this level of expansion. 1 year ago, GAXY could have NEVER taken the $1.5M purchase order they got within the last 2 weeks. Now, they can take that kind of order and fulfill it. You have to look at the larger picture, not the microcosm of only expenditures.
Actually, they are partially right, but also missing one additional key factor that in addition to buying other companies, they were also building up shelf stock of their primary product (interactive panels) which is also an overhead cost. This cost will be offset in future sales, which is where what they said is false and misleading. I think GAXY did the right thing adding debt to secure the future, while the asshats try to paint that as a bad thing, there's the difference. LOL
If you really look at the 10-k, they did spend a lot of cash in the last quarter, but, you have to look closer than that. They spent most of that money on expansion and product. Expansion that is manifesting this quarter in higher sales and revenue, off of product they produced last quarter that is now selling. You have to take the time to look at what is presented compared to current news. GAXY has turned the corner and is growing at an incredible rate right now. Only a short sighted basher would look at a small portion and try to claim otherwise. I'm personally very impressed with their progress and look forward to holding this even longer than I originally planned.
With data out on RTX and now additional data on STI-1499 and STI-2020, nobody really cares when the tests are approved. That being said, it isn't about first, it's about who can make it commercially viable and available. Also, Sorrento's test will allow for point of entry testing for buildings, events, etc. Abbott's still needs a lab and swab. I agree, lots of room in the market.
That's the thing though, as they have worked toward commercialization prior to EUA filing, we don't know what they've accomplished toward shortening the testing time, and reporting of the results. Just have to wait and see.
You missed the 9/21 - Gaxy receives $1.5M purchase order.
New total - $3M, Q1,21
Actually, here are the encouraging things I see here:
- convertible notes and derivative liabilities down a little over half.
- Cost of sales down 34% while revenues increased by 45%
- stock compensation down 14%
- Net Basic and Fully Diluted Loss Per Share improved by 78% over last year
- In general, we have seen as much announcements of revenue contracts since July 1 as was made in all of the last fiscal year. This is a HUGE step forward. (most of that in the last PR we got)
- In general, the majority of the operating loss was acquisition of other companies/product lines.
Brief overview I know and there's more to dig into, but overall, I see this as extremely positive going into the next quarter. Especially what we know of the business they have booked just in the last 3 months from PR, and I'm sure there's more.
Interesting
Regardless of how a season goes or doesn't go, people will still buy merch for their favorite team. LOL, after growing up in Nebraska I can tell you their stuff sells big no matter how they do. I think this is a great deal, and it's good to see they are already exploiting it for more profits. I'm anxious to see how they exploit the rest of the teams in every area of the country.
Wow, 100 stores already. Nice start to that product agreement.
Any muscular, joint or nerve based pain in the body I can definitely see. As a doctor, do you really think it might be effective against say migraines as well? Due to the capsaicin basis of the drug, I would think it may inhibit neurons and thereby be a little risky there. Anxious to hear your thoughts on that as I have many friends that suffer from chronic migraines as well.